According to reports, the Endologix stent graft is an endovascular aneurysm repair device. Unlike other devices of its kind, the Endologix uses a liquid polymer intended to create a low-profile graft with durable aortic seals that adapt to the anatomy of each patient. However, the design also exposes patients to the risks of polymer leaks, according to the company.
In 2018, the Endologix attributed to 47 cases of polymer leak and three deaths to excessive catheter manipulation and other user errors. Last month, Endologix revised its position in an Urgent Medical Device Correction, saying that “a material weakness adjacent to the polymer fill channel” is causing the leaks when it comes under pressure.
According to the company’s statement published Monday:
Despite the failure rate, all Endologix devices will remain on the market. The FDA is asking doctors to factor the risk of polymer leaks into their assessments of the pros and cons of Ovation iX and other approaches. Endologix is advising doctors to monitor for sudden low blood pressure as a possible sign that the polymer is leaking.
Endologix is also working on a newer Alto graft which won FDA approval in March. The company is hoping to transition to Alto by November. CEO John Onopchenko believes that the Alto will “meaningfully decrease polymer leak rates.”
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or medical devices, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.